A federal judge has dismissed all claims against GlaxoSmithKline in the Wellbutrin XL antitrust litigation in which the pharmaceutical giant was accused of delaying the entry of generic versions of the antidepressant medication to market by entering into illegal agreements with generic drug makers to settle patent infringement lawsuits.
U.S. District Judge Mary A. McLaughlin of the Eastern District of Pennsylvania granted GSK’s motion for summary judgment on all claims Wednesday. The litigation was initiated by direct and indirect purchasers of Wellbutrin in 2008. Those plaintiffs argued the Wellbutrin settlement was anti-competitive in nature.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
